$NHI

NATIONAL HEALTH INVESTORS INC (NHI): Results of Operations and Financial Condition

NATIONAL HEALTH INVESTORS INC (NHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Contact: Todd M. Siefert, Chief Financial Officer Phone: (615) 890-9100 NHI Announces Second Quarter 2026 Results MURFREESBORO, Tenn. – (Monday, August 10, 2026) National Health Investors, Inc. (NYSE: NHI) an

Original reporting
Published Aug 10, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$NHI
Bullish
medium confidence
Mentioned
$NHI
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NHIBullishMed
01

Why it matters

Key tradable takeaways are the magnitude of SHOP NOI growth (about 188% YoY), the capital allocation event (sale of the NHC portfolio to reduce leverage), and the earnings bridge signals (EPS up strongly, normalized FFO slightly down, normalized FAD up). These can influence near-term valuation multiples and positioning for REIT income and growth investors.

02

Market read

This is a primary earnings release with quantified operating growth and a major portfolio sale narrative, likely to drive REIT-focused sentiment and positioning.

03

What to watch

Same-store SHOP results were slightly down, and interest income declined while depreciation and G&A rose due to acquisitions and CFO transition costs, which could pressure future normalized metrics.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 10, 2026

Background

National Health Investors, Inc. filed an 8-K with its Q2 2026 results for the quarter ended June 30, 2026, including operating metrics for its Senior Housing Operating Portfolio (SHOP) and Real Estate Investments segment dispositions.

Company-level read

Ticker impact

$NHIBullishMedium confidence
Context

NHI reported Q2 2026 results, including 45.6% YoY growth in diluted EPS to $1.15 and SHOP NOI up about 188% YoY.

Expected impact

Near-term bias upward if investors focus on SHOP NOI acceleration and balance-sheet deleveraging; offset risk if normalized FFO and same-store trends disappoint.

Evidence & confidence

The article is a primary earnings release with multiple quantified metrics (EPS, FFO, FAD, SHOP NOI, dispositions, leverage reduction narrative). However, it lacks full balance-sheet/leverage numbers and forward guidance, limiting precision on magnitude and duration of impact.

Market effects

Reinforces the senior housing REIT narrative of growth via SHOP acquisitions and NOI expansion, while highlighting portfolio sales as a leverage-management tool.

No specific regional demand signal beyond company-wide SHOP portfolio expansion.

Limited global relevance; primarily US senior housing REIT fundamentals and capital allocation.

Counterpoint

Normalized FFO per diluted share fell 2.5% YoY, suggesting that headline EPS strength may be partly driven by dispositions and non-recurring items rather than core cash earnings momentum.

Key entities

  • National Health Investors, Inc.

    NYSE-listed senior housing REIT reporting Q2 2026 results and capital allocation actions, including SHOP expansion and sale of the NHC portfolio.

  • Senior Housing Operating Portfolio (SHOP)

    Operating portfolio whose NOI and same-store performance are highlighted as the core growth engine.

  • NHC portfolio sale

    Sale of a large real estate portfolio described as reducing balance sheet leverage below target range.

Related articles

$NHILow

NATIONAL HEALTH INVESTORS INC (NHI): Completion of Acquisition or Disposition of Assets

NATIONAL HEALTH INVESTORS INC (NHI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. nhi-20260701 0000877860 FALSE 0000877860 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Reported): July 1

$APEIMed

AMERICAN PUBLIC EDUCATION INC (APEI): Results of Operations and Financial Condition

AMERICAN PUBLIC EDUCATION INC (APEI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622572d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 American Public Education Reports Second Quarter 2026 Financial Results ~ Completed Institutional Combination Subsequent to Quarter End, Creating a Single HLC-Accredited Institution ~ ~ Raises Full Year 2026 Revenue, Net

$NKTXMed

Nkarta, Inc. (NKTX): Results of Operations and Financial Condition

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nktx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) • Initia

$TELAMed

TELA Bio, Inc. (TELA): Results of Operations and Financial Condition

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction

$PROKMed

PROKIDNEY CORP. (PROK): Results of Operations and Financial Condition

PROKIDNEY CORP. (PROK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prok-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights • Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for antic